-
Hepa Thera’s HT-101 Secures Breakthrough Therapy Designation from China CDE for Chronic Hepatitis B
Landmark regulatory milestone highlights HT-101’s monotherapy potential to drive HBsAg clearance without immunomodulators.
넶445 2025-07-10
-
Hepa Thera HT-101 Project Summary Meeting Successfully Concludes
On September 28, 2024, the summary meeting for the "Phase I Clinical Study of HT-101 Injection in Healthy Volunteers and Patients with Chronic Hepatitis B Virus Infection," sponsored by Hepa Thera, was successfully held in Beijing.
넶219 2024-09-28
-
Hepa Thera Honored with "VBEF Medical and Health Industry Innovation Product List Top 100"
On May 9, 2024, at the "2024 Future Health 100 Strong Selection" held in Beijing, Hepa Thera was honored with the "VBEF Medical and Health Industry Innovation Product List Top 100".
넶117 2024-05-10
-
Impress at the 3rd Hepatitis Innovation Forum
On March 23rd, the third Hepatitis Innovation Forum, hosted by the China Foundation for Health and Development, took place in Beijing. The forum attracted top experts from basic research, clinical research, and innovative pharmaceutical companies from all over the country to gather and discuss the development trends and challenges in the field of liver disease treatment.
넶157 2024-03-27
-
Hepatitis B Drug HT-101 (siRNA) Receives FDA Clinical Approval
On February 2, 2024, Suzhou Starlight Kunze Biopharmaceutical Co., Ltd. (hereinafter referred to as "Starlight Kunze") announced that its hepatitis B drug candidate HT-101 (siRNA) has received approval from the U.S. FDA to proceed directly to Phase Ib clinical trials for chronic hepatitis B virus infection.
넶172 2024-02-04
-
Hepa Thera Announces First CHB Patient Dosed in HT-101 (Its siRNA Product) Phase 1b Part
This week Suzhou Hepa Thera Biotech Co., Ltd enrolled the first chronic hepatitis B patient in Beijing Friendship Hospital,Capital Medical University for its siRNA product, HT-101. This progress marks HT-101 entering Phase 1b trial, and the trial will be expected to end in the first half year of 2024.
넶267 2023-05-24
-
HT-101 monotherapy with 2 injections achieves surface antigen (HBsAg) seroconversion in 48 weeks! Hepa Thera HT-101 clinical trial makes breakthrough progress!
In the field of hepatitis B treatment, Hepa Thera's HT-101 drug clinical trial has once again brought good news. The latest 48-week follow-up data revealed the drug's significant effect in reducing the levels of hepatitis B surface antigen (HBsAg), especially its astonishing performance at low doses.
넶359 2024-11-08
-
APASL 2025 Live: Hepa Thera Presents New Progress in Functional Cure of Hepatitis B
From March 26th to 30th, 2025, Hepa Thera was invited to participate in the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025 BEIJING).
넶215 2025-04-01
-
Hepathera Unveils Latest Research Findings at AASLD 2025 |Capturing the Forefront of International Hepatology
AASLD is one of the most influential and authoritative international academic conferences in the field of hepatology, dedicated to advancing the development of liver disease research and research workforce, as well as promoting liver health and high-quality patient management. The research team from Hepathera presented its latest research findings as a Late Breaking Parallel Presentation at this year’s conference.
넶41 2025-11-12
-
Hepathera’s HT-101 Injection in Combination with HT-102 Injection Granted Breakthrough Therapy Designation by NMPA
September 23, 2025 – Suzhou Hepathera Biopharmaceutical Co., Ltd. (hereinafter referred to as “Hepathera”) today announced that the combination of its proprietary HT-101 Injection and HT-102 Injection for the treatment of chronic hepatitis B (CHB) has been granted Breakthrough Therapy Designation (BTD) by the National Medical Products Administration (NMPA) of China.
넶23 2025-09-23
-
Hepathera's Innovative Combination Therapy for Chronic Hepatitis B Receives FDA Approval to Initiate Phase II Clinical Trial
On January 19, 2026, Hepathera announced that the Company’s Phase II investigational new drug (IND) application for the combination of its self‑developed HT‑101 and HT‑102 has been cleared by the U.S. Food and Drug Administration (FDA) for the Phase II.
넶44 2026-01-09
-
Hepa Thera appoints Dr. Wu Kai as Chief Executive Officer
On May 6, 2026, Hepa Thera announced the appointment of Dr. Wu Kai as Chief Executive Officer.
넶27 2026-05-06
-
Best Breakthrough Abstract — Hepa Thera to Present Latest Clinical Data at EASL Annual Meeting
Latest Drug Discontinuation Data from HT-101 and HT-102 Combination Therapy Selected as Best Breakthrough Poster at the 2026 EASL Annual Meeting
넶0 2026-05-15
